Crinetics Pharmaceuticals Inc
Company Profile
Business description
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Contact
6055 Lusk Boulevard
San DiegoCA92121
USAT: +1 858 450-6464
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
594
Stocks News & Analysis
stocks
The strange effect of the 30% minimum capital gains tax
stocks
Major ASX miner reduces aluminium exposure
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,004.70 | 38.80 | -0.43% |
| CAC 40 | 8,452.74 | 27.13 | -0.32% |
| DAX 40 | 25,489.26 | 328.63 | -1.27% |
| Dow JONES (US) | 52,821.49 | 234.42 | -0.44% |
| FTSE 100 | 10,687.13 | 35.36 | 0.33% |
| HKSE | 23,496.89 | 119.43 | -0.51% |
| NASDAQ | 25,746.29 | 374.87 | -1.44% |
| Nikkei 225 | 68,256.96 | 1,480.73 | -2.12% |
| NZX 50 Index | 13,762.79 | 0.31 | -0.00% |
| S&P 500 | 7,484.54 | 52.89 | -0.70% |
| S&P/ASX 200 | 8,803.90 | 35.50 | -0.40% |
| SSE Composite Index | 3,990.24 | 51.00 | -1.26% |